Locations:
Abu Dhabi|Canada|Florida|London|Nevada|Ohio|
Gray gradientGray gradient
Cleveland Clinic icon
Consult QD logo
Search IconSearch

Preventive Cardiology

illustrated platelets forming a clot in a blood vessel

Bempedoic Acid Appears to Curb VTE Risk in Statin-Intolerant Patients

Post hoc analysis of CLEAR Outcomes trial bolsters its case as a statin alternative

doctor taking pulse of a woman in an exam room

Counseling Patients on the New Cholesterol Guideline: What Providers Should Know

How to talk about lifetime risk, treatment goals, Lp(a) testing, statin skepticism and more

stylized scientific illustration of hormone receptors

Dual-Agonist Incretin Therapy Outshines GLP-1 Agonist in Broad Cardiorenal Outcomes

Post hoc analysis of SURPASS-CVOT trial has implications for future cardiovascular outcome trials

LDL cholesterol particle with a DNA double helix on top of it

CRISPR-Cas9 Gene Editing for Refractory Dyslipidemia Shows Safety and Preliminary Efficacy

First-in-human phase 1 trial induced loss of function in gene that codes for ANGPTL3

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

LDL cholesterol particles floating in bloodstream

Obicetrapib-Ezetimibe Combo Therapy Halves LDL Cholesterol Levels Relative to Placebo

Phase 3 TANDEM study may help pave way to first approval of a CETP inhibitor

lipoprotein(a) particle

Large Cohort Study Reveals Vanishingly Small Rates of Lipoprotein(a) Testing

Yet 21.4% of tested individuals had Lp(a) elevation

Lp(a) particles floating among red blood cells

Lepodisiran’s Large, Durable Lp(a) Reductions in Phase 2 Trial Boost Anticipation of Phase 3 Results

Small interfering RNA lowered lipoprotein(a) by 94% during six-month follow-up after a single dose

blood pressure cuff on a woman's arm

Lorundrostat Shows Continued Promise Against Uncontrolled Hypertension

Phase 2b trial of aldosterone synthase inhibitor also finds no benefit from dose escalation

edge of an apolipoprotein particle

Small-Interfering RNA Shows Cumulative Lp(a) Reduction With Successive Doses

Phase 2 trial of zerlasiran yields first demonstration of longer effect with each dose of an siRNA

gut microbes in the human intestine

Gut Microbial TMAO Pathway Associated With Incident Heart Failure

Metabolites from animal product substrates implicated in heart failure development in community cohorts

BackPage 1 of 5Next

Advertisement

Ad